Minimum inhibitory concentration
In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.
The MIC is determined by preparing solutions of the chemical in vitro at increasing concentrations, incubating the solutions with the separate batches of cultured bacteria, and measuring the results using agar dilution or broth microdilution. Results have been graded into susceptible (often called sensitive), intermediate, or resistant to a particular antimicrobial by using a breakpoint. Breakpoints are agreed upon values, published in guidelines of a reference body, such as the U.S. Clinical and Laboratory Standards Institute (CLSI), the British Society for Antimicrobial Chemotherapy (BSAC) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). There have been major discrepancies between the breakpoints from various European countries over the years, and between those from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the US Clinical and Laboratory Standards Institute (CLSI). 
While MIC is the lowest concentration of an antibacterial agent necessary to inhibit visible growth, minimum bactericidal concentration (MBC) is the minimum concentration of an antibacterial agent that results in bacterial death. The closer the MIC is to the MBC, the more bactericidal the compound.
The first step in drug discovery is often the screening of a library drug candidate for MICs against bacteria of interest. As such, MICs are usually the starting point for larger pre-clinical evaluations of novel antimicrobial agents.
After the discovery and commercialization of antibiotics, Alexander Fleming developed the broth dilution technique using the turbidity of the broth for assessment. This is commonly believed to be the conception point of minimum inhibitory concentrations. Later in the 1980s, Clinical and Laboratory Standards Institute has consolidated the methods and standards for MIC determination and clinical usage. Following the discovery of new antibacterials, pathogens and their evolution, the protocols by CLSI are also continually updated to reflect that change. The protocols and parameters set by CLSI are considered to be the "gold standard" in the United States and are used by regulatory authorities, such as the FDA, to make evaluations.
Nowadays, the MIC is used in antimicrobial susceptibility testing. In clinics, more often than not, exact pathogens cannot be easily determined by symptoms of the patient. Then, even if the pathogen is determined, different serotypes of pathogens, such as Staphylococcus aureus, have varying levels of resistance to antimicrobials. As such, it is difficult to prescribe correct antimicrobials. The MIC is determined in such cases by growing the pathogen isolate from the patient on plate or broth, which is later used in the assay. Thus, knowledge of the MIC will provide a physician valuable information for making a prescription. Accurate and precise usage of antimicrobials is also important in the context of multi-drug resistant bacteria. Microbes such as bacteria have been gaining resistance to antimicrobials they were previously susceptible to. Usage of incompatible or sub-MIC levels of antibicrobials provides the selective pressure that has hastened the evolution of resistance in bacterial pathogens. As such, it is increasingly important to determine the MIC in order make the best choice in prescribing antimicrobials.
MIC is used clinically over MBC because MIC is more easily determined. Minimum bactericidal concentration (MBC), which is the minimum antibacterial concentration resulting in microbial death, is defined by the inability to re-culture bacteria. In addition, drug effectiveness is generally similar when taken at both MIC and MBC concentrations because the host immune system can expel the pathogen when bacterial proliferation is at a standstill. When the MBC is much higher than the MIC, drug toxicity makes taking the MBC of the drug detrimental to patient. Antimicrobial toxicity can come in many forms, such as immune hypersensitivity and off-target toxicity.
Broth dilution assay
There are three main reagents necessary to run this assay: the media, an antimicrobial agent, and the microbe being tested. The most commonly used media is cation-adjusted Mueller Hinton Broth, due to its ability to support the growth of most pathogens and its lack of inhibitors towards common antibiotics. Depending on the pathogen and antibiotics being tested, the media can be changed and/or adjusted. The antimicrobial concentration is adjusted into the correct concentration by mixing stock antimicrobial with media. The adjusted antimicrobial is serially diluted into multiple tubes (or wells) to obtain a gradient. The dilution rate can be adjusted depending on the breakpoint and the practitioner's needs. The microbe, or the inoculating agent, must come from the same colony-forming unit, and must be at the correct concentration. This may be adjusted by incubation time and dilution. For verification, the positive control is plated in a hundred fold dilution to count colony forming units. The microbes inoculate the tubes (or plate) and are incubated for 16–20 hours. The MIC is generally determined by turbidity.
- McKinnon, PS and Davis, SL. Pharmokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. in: VL Yu, G Edwards, PS McKinnon, C Peloquin, G Morse (Eds.) Antimicrobial therapy and vaccines, volume II: antimicrobial agents. ESun Technologies, Pittsburgh, PA; 2005: 5–19
- Andrews, J. M. (1 July 2001). "Determination of minimum inhibitory concentrations". Journal of Antimicrobial Chemotherapy. 48 (suppl 1): 5–16. doi:10.1093/jac/48.suppl_1.5. PMID 11420333.
- Seydina M Diene, Cédric Abat, Jean-Marc Rolain, Didier Raoult. How artificial is the antibiotic resistance definition? Lancet Infectious Diseases, Volume 17, No. 7, p690, July 2017. DOI: https://dx.doi.org/10.1016/S1473-3099(17)30338-9
- Tripathi, K.D. (2013). Essentials of Medical Pharmacology (7th ed.). New Delhi, India: Jaypee Brothers Medical Publishers. pp. 696, 697. ISBN 9789350259375.
- Turnidge JD, Ferraro MJ, Jorgensen JH (2003) Susceptibility Test Methods: General Considerations. In PR Murray, EJ Baron, JH Jorgensen, MA Pfaller, RH Yolken. Manual of Clinical Microbiology. 8th Ed. Washington. American Society of Clinical Microbiology. p 1103 ISBN 1-55581-255-4
- O'Neill, AJ; Chopra, I (August 2004). "Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques". Expert Opinion on Investigational Drugs. 13 (8): 1045–63. doi:10.1517/13543718.104.22.1685. PMID 15268641.
- 1881-1955., Fleming, Alexander, Sir (1944). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. H.K. Lewis. OCLC 25424051.
- Wheat, Philip F. (July 2001). "History and development of antimicrobial susceptibility testing methodology". Journal of Antimicrobial Chemotherapy. 48 (suppl_1): 1–4. doi:10.1093/jac/48.suppl_1.1. ISSN 1460-2091.
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard. Cockerill, Franklin R., Clinical and Laboratory Standards Institute. (9th ed.). Wayne, Pa: Clinical and Laboratory Standards Institute. 2012. ISBN 978-1562387846. OCLC 1016466655.
- Performance standards for antimicrobial susceptibility testing : twenty-second informational supplement. Cockerill, F. (Franklin), Clinical and Laboratory Standards Institute. Wayne, PA: Clinical and Laboratory Standards Institute. 2012. ISBN 978-1562387853. OCLC 795927370.
- Cameron, D. R.; Howden, B. P.; Peleg, A. Y. (2011-08-24). "The Interface Between Antibiotic Resistance and Virulence in Staphylococcus aureus and Its Impact Upon Clinical Outcomes". Clinical Infectious Diseases. 53 (6): 576–582. doi:10.1093/cid/cir473. ISSN 1058-4838. PMID 21865195.
- Antimicrobial susceptibility testing protocols. Schwalbe, Richard., Steele-Moore, Lynn., Goodwin, Avery C. Boca Raton: CRC Press. 2007. ISBN 9781420014495. OCLC 666899344.
- Organization, World Health (2015-12-15). Global antimicrobial resistance surveillance system : manual for early implementation. World Health Organization. Geneva, Switzerland. ISBN 978-9241549400. OCLC 950637154.
- Geisinger, Edward; Isberg, Ralph R. (2017-02-15). "Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria". The Journal of Infectious Diseases. 215 (suppl_1): S9–S17. doi:10.1093/infdis/jiw402. ISSN 0022-1899. PMC 5853982. PMID 28375515.
- author., Gallagher, Jason C. (2016-11-21). Antibiotics simplified. ISBN 9781284111293. OCLC 952657550.
- Guengerich, F. Peter (2011). "Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development". Drug Metabolism and Pharmacokinetics. 26 (1): 3–14. doi:10.2133/dmpk.DMPK-10-RV-062. ISSN 1347-4367. PMC 4707670. PMID 20978361.
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard. Cockerill, F. (Franklin), Clinical and Laboratory Standards Institute. (Tenth ed.). Wayne, Pa.: Clinical and Laboratory Standards Institute. 2015. ISBN 978-1562387839. OCLC 932608948.